Phase II study of bortezomib dexamethasone and high-dose melphalan in patients with relapse after high-dose melphalan with autologous stem cell support.

Trial Profile

Phase II study of bortezomib dexamethasone and high-dose melphalan in patients with relapse after high-dose melphalan with autologous stem cell support.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2015

At a glance

  • Drugs Bortezomib; Dexamethasone; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2010 Planned end date changed from 1 Jul 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 17 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top